Tinea Versicolor Workup: Laboratory Studies, Histologic …

Crespo-Erchiga V, Florencio VD. Malassezia yeasts and pityriasis versicolor. Curr Opin Infect Dis. 2006 Apr. 19(2):139-47. [Medline].

Gaitanis G, Velegraki A, Alexopoulos EC, Chasapi V, Tsigonia A, Katsambas A. Distribution of Malassezia species in pityriasis versicolor and seborrhoeic dermatitis in Greece. Typing of the major pityriasis versicolor isolate M. globosa. Br J Dermatol. 2006 May. 154(5):854-9. [Medline].

Morishita N, Sei Y, Sugita T. Molecular analysis of malassezia microflora from patients with pityriasis versicolor. Mycopathologia. 2006 Feb. 161(2):61-5. [Medline].

Rincon S, Celis A, Sopo L, Motta A, Cepero de Garcia MC. Malassezia yeast species isolated from patients with dermatologic lesions. Biomedica. 2005 Jun. 25(2):189-95. [Medline].

Krisanty RI, Bramono K, Made Wisnu I. Identification of Malassezia species from pityriasis versicolor in Indonesia and its relationship with clinical characteristics. Mycoses. 2009 May. 52(3):257-62. [Medline].

Prohic A, Jovovic Sadikovic T, Krupalija-Fazlic M, Kuskunovic-Vlahovljak S. Malassezia species in healthy skin and in dermatological conditions. Int J Dermatol. 2016 May. 55 (5):494-504. [Medline].

Nakabayashi A, Sei Y, Guillot J. Identification of Malassezia species isolated from patients with seborrhoeic dermatitis, atopic dermatitis, pityriasis versicolor and normal subjects. Med Mycol. 2000 Oct. 38 (5):337-41. [Medline].

Tarazooie B, Kordbacheh P, Zaini F, Zomorodian K, Saadat F, Zeraati H, et al. Study of the distribution of Malassezia species in patients with pityriasis versicolor and healthy individuals in Tehran, Iran. BMC Dermatol. 2004 May 1. 4:5. [Medline].

Blaes AH, Cavert WP, Morrison VA. Malassezia: is it a pulmonary pathogen in the stem cell transplant population?. Transplant Infectious Disease. August, 2009. 11:313-317. [Medline].

Muhammad N, Kamal M, Islam T, Islam N, Shafiquzzaman M. A study to evaluate the efficacy and safety of oral fluconazole in the treatment of tinea versicolor. Mymensingh Med J. 2009 Jan. 18(1):31-5. [Medline].

He SM, Du WD, Yang S, et al. The genetic epidemiology of tinea versicolor in China. Mycoses. 2008 Jan. 51(1):55-62. [Medline].

Burkhart CG, Dvorak N, Stockard H. An unusual case of tinea versicolor in an immunosuppressed patient. Cutis. 1981. 27(1):56-8. [Medline].

Gulec AT, Demirbilek M, Seckin D, et al. Superficial fungal infections in 102 renal transplant recipients: a case-control study. J Am Acad Dermatol. 2003 Aug. 49(2):187-92. [Medline].

Mendez-Tovar LJ. Pathogenesis of dermatophytosis and tinea versicolor. Clinics in Dermatology. 2010. 28:185-188. [Medline].

Fungal Diseases. Bolognia J, Jorizzo JL, Schaffer JV, eds. Dermatology. 3rd ed. Philadelphia, Pa: Elsevier Saunders; 2012. Vol 2: 1251-55.

Kilic M, Oguztuzum S, Karadag S, Cakir E, Aydin M, Ozturk L. Expression of GSTM4 and GSTT1 in patients with Tinea versicolor, Tinea inguinalis, and Tinea pedis infections: a preliminary study. Clinical Dermatology. 2011. 36:590-594. [Medline].

Haiduk J, Treudler R, Ziemer M. Atrophying tinea versicolor with epidermal atrophy. J Dtsch Dermatol Ges. 2016 Jul. 14 (7):740-3. [Medline].

Cullingham K, Hull PR. Atrophying pityriasis versicolor. CMAJ. 2014 Jul 8. 186 (10):776. [Medline].

Tatnall FM, Rycroft RJ. Pityriasis versicolor with cutaneous atrophy induced by topical steroid application. Clin Exp Dermatol. 1985 May. 10 (3):258-61. [Medline].

Crowson AN, Magro CM. Atrophying tinea versicolor: a clinical and histological study of 12 patients. Int J Dermatol. 2003 Dec. 42 (12):928-32. [Medline].

Levy JM, Magro C. Atrophying pityriasis versicolor as an idiosyncratic Tcell-mediated response to Malassezia: A case series. J Am Acad Dermatol. 2016 Nov 2. [Medline].

Zhou H, Tang XH, De Han J, Chen MK. Dermoscopy as an ancillary tool for the diagnosis of pityriasis versicolor. J Am Acad Dermatol. 2015 Dec. 73 (6):e205-6. [Medline].

Errichetti E, Stinco G. Dermoscopy in General Dermatology: A Practical Overview. Dermatol Ther (Heidelb). 2016 Dec. 6 (4):471-507. [Medline].

Suwattee P, Cham PM, Solomon RK, Kaye VN. Tinea versicolor with interface dermatitis. J Cutan Pathol. 2009 Feb. 36(2):285-6. [Medline].

Romano C, Maritati E, Ghilardi A, Miracco C, Mancianti F. A case of pityriasis versicolor atrophicans. Mycoses. 2005 Nov. 48 (6):439-41. [Medline].

Lim SL, Lim CS. New contrast stain for the rapid diagnosis of pityriasis versicolor. Arch Dermatol. 2008 Aug. 144(8):1058-9. [Medline].

Janaki C, Sentamilselvi G, Janaki VR, Boopalraj JM. Unusual observations in the histology of Pityriasis versicolor. Mycopathologia. 1997. 139(2):71-4. [Medline].

Gupta AK, Lyons DC. Pityriasis versicolor: an update on pharmacological treatment options. Expert Opin Pharmacother. 2014 Aug. 15(12):1707-13. [Medline].

Gupta AK, Skinner AR. Ciclopirox for the treatment of superficial fungal infections: a review. Int J Dermatol. 2003 Sep. 42 Suppl 1:3-9. [Medline].

Sepaskhah M, Sadat MS, Pakshir K, Bagheri Z. Comparative efficacy of topical application of tacrolimus and clotrimazole in the treatment of pityriasis versicolor: A single blind, randomised clinical trial. Mycoses. 2017 Jan 25. [Medline].

Hull CA, Johnson SM. A double-blind comparative study of sodium sulfacetamide lotion 10% versus selenium sulfide lotion 2.5% in the treatment of pityriasis (tinea) versicolor. Cutis. 2004 Jun. 73(6):425-9. [Medline].

Vermeer BJ, Staats CC. The efficacy of a topical application of terbinafine 1% solution in subjects with pityriasis versicolor: a placebo-controlled study. Dermatology. 1997. 194 Suppl 1:22-4. [Medline].

Carrillo-Munoz AJ, Giusiano G, Ezkurra PA, Quindos G. Sertaconazole: updated review of a topical antifungal agent. Expert Rev Anti Infect Ther. 2005 Jun. 3(3):333-42. [Medline].

Gold M, Bridges T, Avakian E, Plaum S, Pappert EJ, Fleischer AB, et al. An open-label study of naftifine hydrochloride 1% gel in the treatment of tinea versicolor. Skin Med. Sept 2011. 9:283-6. [Medline].

Croxtall J, Plosker G. Sertaconazole: a reviw of its use in the management of superficial mycoses in dermatology and gynacology. Ingenta/Adis International. Jan 2009. 69:339-359. [Medline].

Cantrell WC, Elewksi BE. Can pityriasis versicolor be treated with 2% ketoconazole foam?. J Drugs Dermatol. 2014 Jul 1. 13(7):855-9. [Medline].

U.S. Food and Drug Administration. Nizoral (ketoconazole) oral tablets: Drug Safety Communication - Prescribing for unapproved uses including skin and nail infections continues; linked to patient death. FDA Medwatch. May 19, 2016. Available at http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm502073.htm.

Hickman JG. A double-blind, randomized, placebo-controlled evaluation of short-term treatment with oral itraconazole in patients with tinea versicolor. J Am Acad Dermatol. 1996 May. 34(5 Pt 1):785-7. [Medline].

Karakas M, Durdu M, Memisoglu HR. Oral fluconazole in the treatment of tinea versicolor. J Dermatol. 2005 Jan. 32(1):19-21. [Medline].

Partap R, Kaur I, Chakrabarti A, Kumar B. Single-dose fluconazole versus itraconazole in pityriasis versicolor. Dermatology. 2004. 208(1):55-9. [Medline].

Wahab MA, Ali ME, Rahman MH, Chowdhury SA, Monamie NS, Sultana N, et al. Single dose (400mg) versus 7 day (200mg) daily dose itraconazole in the treatment of tinea versicolor: a randomized clinical trial. Mymensingh Med J. 2010 Jan. 19(1):72-6. [Medline].

Faergemann J, Todd G, Pather S, et al. A double-blind, randomized, placebo-controlled, dose-finding study of oral pramiconazole in the treatment of pityriasis versicolor. J Am Acad Dermatol. 2009 Dec. 61(6):971-6. [Medline].

Gupta AK, Lane D, Paquet M. Systematic review of systemic treatments for tinea versicolor and evidence-based dosing regimen recommendations. J Cutan Med Surg. 2014 Mar-Apr. 18(2):79-90. [Medline].

Mellen LA, Vallee J, Feldman SR, Fleischer AB Jr. Treatment of pityriasis versicolor in the United States. J Dermatolog Treat. 2004 Jun. 15(3):189-92. [Medline].

Leeming JP, Sansom JE, Burton JL. Susceptibility of Malassezia furfur subgroups to terbinafine. Br J Dermatol. 1997 Nov. 137(5):764-7. [Medline].

Faergemann J, Gupta AK, Al Mofadi A, Abanami A, Shareaah AA, Marynissen G. Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. Arch Dermatol. 2002 Jan. 138(1):69-73. [Medline].

Kim YJ, Kim YC. Successful treatment of pityriasis versicolor with 5-aminolevulinic acid photodynamic therapy. Arch Dermatol. 2007 Sep. 143(9):1218-20. [Medline].

Qiao J, Li R, Ding Y, Fang H. Photodynamic therapy in the treatment of superficial mycoses: an evidence-based evaluation. Mycopathologia. 2010. 170:339-343. [Medline].

Fernandez-Nava HD, Laya-Cuadra B, Tianco EA. Comparison of single dose 400 mg versus 10-day 200 mg daily dose ketoconazole in the treatment of tinea versicolor. Int J Dermatol. 1997 Jan. 36(1):64-6. [Medline].

Burkhart CG. Tinea versicolor. J Dermatol Allergy. 1983. 6:8-12.

See the original post here:
Tinea Versicolor Workup: Laboratory Studies, Histologic ...

Related Post

Comments are closed.